L A Valentino
Overview
Explore the profile of L A Valentino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Mackensen S, Hilberg T, Valentino L, Kurnik K, Khair K
Haemophilia
. 2018 Jul;
24(6):888-895.
PMID: 30004619
Introduction: Contemporary haemophilia management recommends sport and physical activity in children with haemophilia. Assessment of subjective physical functioning requires standardized and validated instruments. Aims: To adapt and psychometrically test the...
2.
Carpenter S, Khair K, Gringeri A, Valentino L
Haemophilia
. 2018 Jun;
24(4):570-577.
PMID: 29901839
The development of high-titre inhibitory antibodies (inhibitors) against factor VIII (FVIII) remains a challenge in the management of patients with haemophilia A (HA). Patients with high-titre inhibitors are more likely...
3.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, et al.
Haemophilia
. 2017 Mar;
23(3):e170-e179.
PMID: 28345268
Background: Prophylactic replacement with factor concentrate is the optimal treatment for persons with severe haemophilia to avoid or minimize bleeding. This ultimately prevents or reduces joint disease and improves life...
4.
Hakobyan N, Valentino L, Cong L, Enockson C, Song X, Desai S, et al.
Haemophilia
. 2016 Jul;
22(5):790-8.
PMID: 27456473
Introduction: The prophylactic administration of clotting factor concentrate is currently the most effective strategy for the prevention of joint bleeding. As new agents with different mechanisms of action and administration...
5.
Valentino L, Pipe S, Collins P, Blanchette V, Berntorp E, Fischer K, et al.
Haemophilia
. 2016 Mar;
22(4):514-20.
PMID: 26930418
Introduction: We previously showed that pharmacokinetic-guided prophylaxis (PKP) allows the dosing interval to be extended while maintaining a specific trough level. However, the associations of peak factor VIII (FVIII) levels...
6.
Oladapo A, Epstein J, Williams E, Ito D, Gringeri A, Valentino L
Haemophilia
. 2015 Sep;
21(5):e344-58.
PMID: 26390060
Introduction: Prophylaxis is effective in reducing the number of bleeding episodes in patients with severe or moderately severe haemophilia A and B, including those with inhibitors. However, data, predominantly from...
7.
Valentino L, Holme P
Haemophilia
. 2015 Jun;
21(6):709-14.
PMID: 26036756
Inhibitor development in haemophilia patients is challenging especially when undergoing surgical procedures. The development of an inhibitor precludes using factor VIII (FVIII) therapy thereby requiring a bypassing agent (BPA) for...
8.
Valentino L, Kempton C, Kruse-Jarres R, Mathew P, Meeks S, Reiss U
Haemophilia
. 2015 Jun;
21(5):559-67.
PMID: 26032231
Introduction: The development of anti-factor VIII (FVIII) antibodies (inhibitors) is the most serious treatment-related complication in patients with hemophilia A, rendering standard replacement therapy ineffective, heightening the risk for uncontrollable...
9.
Mittal N, Naridze R, James P, Shott S, Valentino L
Haemophilia
. 2015 May;
21(6):806-11.
PMID: 25982122
Unlabelled: von Willebrand disease (VWD), an inherited bleeding disorder caused by deficiency or dysfunction of von Willebrand factor (VWF) is diagnosed when a personal and often a family history of...
10.
Rodriguez-Merchan E, Valentino L
Haemophilia
. 2015 Apr;
21(4):411-8.
PMID: 25854422
Many paediatric patients with haemophilia who might benefit from radiosynovectomy (RS) for the control of synovitis do not undergo the procedure as there is controversy in the literature regarding the...